Aravive (FRA:VE11) Short-Term Capital Lease Obligation : €1.99 Mil (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Aravive Short-Term Capital Lease Obligation?

Aravive's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was €1.99 Mil.

Aravive's quarterly Short-Term Capital Lease Obligation declined from Mar. 2023 (€2.03 Mil) to Jun. 2023 (€1.98 Mil) but then increased from Jun. 2023 (€1.98 Mil) to Sep. 2023 (€1.99 Mil).

Aravive's annual Short-Term Capital Lease Obligation increased from Dec. 2020 (€1.72 Mil) to Dec. 2021 (€2.03 Mil) and increased from Dec. 2021 (€2.03 Mil) to Dec. 2022 (€2.07 Mil).

Aravive Short-Term Capital Lease Obligation Historical Data

The historical data trend for Aravive's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Short-Term Capital Lease Obligation Chart

Aravive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.15

1.72

2.03

2.07

Aravive Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															2.24	2.07	2.03	1.98	1.99

Aravive Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Aravive Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Aravive's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Aravive (FRA:VE11) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (FRA:VE11) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ARAV:USA

Address

3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098

Website

https://www.aravive.com

Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive (FRA:VE11) Headlines

No Headlines